MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/220/0.1/21.03.25 | Market Closed - Börse Stuttgart 12:07:26 2024-06-06 pm EDT | ||
| 0.19 EUR | +8.57% |
|
| Current month | +47.29% | ||
| 1 month | +33.80% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-06 | 0.19 | +8.57% |
| 24-06-05 | 0.175 | +8.70% |
| 24-06-04 | 0.161 | +19.26% |
| 24-06-03 | 0.135 | +4.65% |
| 24-05-31 | 0.129 | +9.32% |
Delayed Quote Börse Stuttgart
Last update June 06, 2024 at 12:07 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | ME9ZN2 |
| ISIN | DE000ME9ZN23 |
| Date issued | 2024-03-11 |
| Strike | 220 $ |
| Maturity | 2025-03-21 (288 Days) |
| Parity | 10 : 1 |
| Emission price | 0.43 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.35 € |
|---|---|
| Lowest since issue | 0.105 € |
| Spread | 0.006 € |
| Spread % | 3.05% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
973.3
DKK
Average target price
920
DKK
Spread / Average Target
-5.48%
- Stock Market
- Warrants
- Warrant
